MG217 Multi-Symptom Treatment Cream & Skin Protectant (colloidal oatmeal 2%) recall — Wisconsin Pharmacal Company (Class I)

Wisconsin Pharmacal Company is recorded by the U.S. Food and Drug Administration (FDA) as recalling MG217 Multi-Symptom Treatment Cream & Skin Protectant (colloidal oatmeal 2%) — a Class I recall, initiated 2026-04-24 and posted to the FDA enforcement report on 2026-05-27, under recall number D-0553-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Microbial Contamination of Non-Sterile Products: confirmed presence of Staphylococcus Aureus.”. From the product description, the form is cream and the strengths given are 2% and 170 g. Distribution is recorded as “USA Nationwide and Bahamas” — Nationwide (US), with the recalling firm on record in WI, United States. It is the only recall number the FDA has filed under event ID 98788. 33 days separate the firm's initiation date from the FDA's report date on this record. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0553-2026
FDA event ID 98788
Classification Class I (most serious regulatory tier)
Status Ongoing
Recalling firm Wisconsin Pharmacal Company
Recall initiated 2026-04-24
Reported by FDA 2026-05-27
Report lag 33 days from initiation to report
Distribution USA Nationwide and Bahamas — Nationwide (US)
Firm location on record WI, United States
Product description (source) MG217 Multi-Symptom Treatment Cream & Skin Protectant (colloidal oatmeal 2%), NET WT 6 oz (170 g), Manufactured by: Pharmacal 1 Pharmacal Way, P.O. Box 198, Jackson, WI 53037.

Reason reported by FDA

Microbial Contamination of Non-Sterile Products: confirmed presence of Staphylococcus Aureus.

10 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

4 identifying values matched by exact pattern in the 28-word product description above; each is a literal substring of it.

Product named MG217 Multi-Symptom Treatment Cream & Skin Protectant (colloidal oatmeal 2%)
Form Cream
Strength 2% · 170 g
Manufactured by Pharmacal 1 Pharmacal Way, P.O. Box 198

Reported in the same month (2026-05)

48 enforcement reports carry a report date in 2026-05; these 1 are the Class I ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
Lactated Ringer's Injection USP, 1000 mLD-0540-2026B Braun Medical IncClass I2026-05-13

Nearest Class I recalls by date

11 of 250 indexed records share the Class I tier; the 9 nearest to 2026-05-27 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
DOXOrubin Hydrochloride Liposome injection, 50 mg/25 mLD-0580-2026Sun Pharmaceutical Industries Inc50 mg/25 mL · Injection2026-06-17
Gas-X Extra Strength, 125 mgD-0595-2026Haleon US Holdings LLC125 mg · Softgels2026-06-17
BEEKEEPER'S NATURALS Saline Nasal Spray, 30 mLD-0620-2026Beekeeper's Naturals Usa Inc.30 mL · Nasal Spray2026-06-17
BD ChloraPrep Clear, 2%D-0624-2026Carefusion 213, LLC2% · Solution2026-07-01
BD ChloraPrep FREPP Clear, 2%D-0625-2026Carefusion 213, LLC2% · Solution2026-07-01
Revitaderm Wound Care Gel, 0.1%D-0692-2026Blaine Labs Inc0.1% · Gel2026-07-08
Cetirizine Hydrochloride Tablets USP 5 mgD-0732-2026JB Chemicals And Pharmaceuticals Ltd5 mg · Tablets2026-07-29
Cyclophosphamide for Injection, 1 gram/vialD-0743-2026Sunny Pharmtech Inc.1 gram/vial · for Injection2026-08-12
Cyclophosphamide for Injection, 2 gram/vialD-0744-2026Sunny Pharmtech Inc.2 gram/vial · for Injection2026-08-12

Reading this record

Class I is the FDA's own severity tier for the recall action — 11 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual.

Namespace context: the Class I index (11 records) and the recall hub (250 records, 118 FDA events); Wisconsin Pharmacal Company (1 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0553-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0553-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-05-27
Ingested
2026-08-22
Record hash
505ff288767e4cd5

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.